A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer

作者: Niusha Samadaian , Pouya Salehipour , Mohsen Ayati , Naser Rakhshani , Ali Najafi

DOI: 10.1016/J.PRP.2018.09.019

关键词:

摘要: Abstract Deregulation of key signaling pathways is one the primary phenomena in carcinogenesis. DAB2IP and SPRY2 are regulatory elements, which act as feedback inhibitors receptor tyrosine kinases mitogen-activated protein kinase pathway. These elements have also been implicated pathophysiology cancer. Therefore, this study aimed to investigate expression all known splice variants prostate tissue. Fresh Prostate tissue samples (50 cancer/ matched normal 30 BPH) were collected total RNA was extracted followed by cDNA synthesis. The transcript evaluated using RT-PCR quantitative Real-time PCR. results indicated significant down-regulation variant 1 cancerous tissues compared paired (P = 0.001) well 2 comparison with counterparts BPH (P = 0.008 P = 0.025, respectively). In addition, there a negative correlation between DAB2IP.1 SPRY2.2 PSA levels cancer (P = 0.039 ρ =−0.24 P = 0.045 =−0.3, Interestingly, mRNA positively correlated tumor (P = 0.002 ρ = 0.434). For first time, experiment highlights deregulation human present confirms extends previous reports through indicating transcript-specific association tumorigenesis.

参考文章(35)
Hongzhu Qu, Xiangdong Fang, A Brief Review on the Human Encyclopedia of DNA Elements (ENCODE) Project Genomics, Proteomics & Bioinformatics. ,vol. 11, pp. 135- 141 ,(2013) , 10.1016/J.GPB.2013.05.001
H Dote, S Toyooka, K Tsukuda, M Yano, T Ota, M Murakami, M Naito, M Toyota, A F Gazdar, N Shimizu, Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour British Journal of Cancer. ,vol. 92, pp. 1117- 1125 ,(2005) , 10.1038/SJ.BJC.6602458
Hong Chen, Shinichi Toyooka, Adi F. Gazdar, Jer-Tsong Hsieh, Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. Journal of Biological Chemistry. ,vol. 278, pp. 3121- 3130 ,(2003) , 10.1074/JBC.M208230200
Wai-Kin So, Jung-Chien Cheng, Qianlan Fan, Alice S.T. Wong, David G. Huntsman, C. Blake Gilks, Peter C.K. Leung, Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion☆ FEBS Letters. ,vol. 589, pp. 302- 309 ,(2015) , 10.1016/J.FEBSLET.2014.12.012
Yi‐Jun Shen, Zhao‐Lu Kong, Fang‐Ning Wan, Hong‐Kai Wang, Xiao‐Jie Bian, Hua‐Lei Gan, Chao‐Fu Wang, Ding‐Wei Ye, Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer Cancer Science. ,vol. 105, pp. 704- 712 ,(2014) , 10.1111/CAS.12407
Ting Ling Lo, Chee Wai Fong, Permeen Yusoff, Arthur B. Mckie, Mei-Sze Chua, Hing Y. Leung, Graeme R. Guy, Sprouty and cancer : The first terms report Cancer Letters. ,vol. 242, pp. 141- 150 ,(2006) , 10.1016/J.CANLET.2005.12.032
Ophélia Maertens, Karen Cichowski, An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer Advances in Biological Regulation. ,vol. 55, pp. 1- 14 ,(2014) , 10.1016/J.JBIOR.2014.04.002
D. Xie, C. Gore, J. Liu, R.-C. Pong, R. Mason, G. Hao, M. Long, W. Kabbani, L. Yu, H. Zhang, H. Chen, X. Sun, D. A. Boothman, W. Min, J.-T. Hsieh, Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 2485- 2490 ,(2010) , 10.1073/PNAS.0908133107
Masaaki Yano, Shinichi Toyooka, Kazunori Tsukuda, Hideaki Dote, Mamoru Ouchida, Tetsuro Hanabata, Motoi Aoe, Hiroshi Date, Adi F. Gazdar, Nobuyoshi Shimizu, Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. International Journal of Cancer. ,vol. 113, pp. 59- 66 ,(2005) , 10.1002/IJC.20531
Susie A. Lee, Coral Ho, Ritu Roy, Cynthia Kosinski, Mohini A. Patil, Aaron D. Tward, Jane Fridlyand, Xin Chen, Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Hepatology. ,vol. 47, pp. 1200- 1210 ,(2007) , 10.1002/HEP.22169